SEOM guidelines: non-seminomatous germ cell cancer (NSGCC)

• Autores: Xavier García del Muro Solans, Javier Sastre Valera, Dolores Isla Casado
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 13, Nº. 8, 2011, págs. 565-568
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Non-seminomatous germ cell cancer (NSGCC) is a curable disease; its treatment has not essentially changed since the 1980s. BEP (bleomycin, etoposide, cisplatin) chemotherapy remains the standard of care. NSGCC�s management can be summarised by three trees of decision, which contemplate staging, treatment with chemotherapy and management of postchemotherapy residual disease. The role of high-dose chemotherapy remains to be established. TIP (paclitaxel, iposfamide, cisplatin) chemotherapy is still the standard salvage treatment for patients progressing after BEP chemotherapy. Surgical removal of any residual disease is mandatory. For patients with poor prognosis, consultation with a centre of expertise is strongly recommended.